Literature DB >> 443691

Bromocriptine and endocrine disorders.

R F Spark, G Dickstein.   

Abstract

Bromocriptine, a dopaminergic agonist, has been used to treat many endocrine disorders. In hyperprolactinemia associated with galactorrhea, amenorrhea, oligospermia, and impotence, bromocriptine reduces prolactin levels to normal and allows for satisfactory return of sexual and reproductive function in 90% of patients. In acromegaly, bromocriptine brings about subjective improvement in 75% of patients with reduction in growth-hormone levels to normal in 22% of patients. Bromocriptine has been used in premenstrual tension, functional infertility, Nelson's syndrome, and Cushing's disease with variable benefit. In low doses, side-effects are minimal. In higher doses, digital vasospasm and gastrointestinal bleeding have occurred. Although bromocriptine has been used in a wide variety of endocrine disorders, it appears to be most useful in treatment of male and female infertility associated with hyperprolactinemia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 443691     DOI: 10.7326/0003-4819-90-6-949

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  6 in total

1.  Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.

Authors:  A B Atkinson; A L Kennedy; B Sheridan
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

3.  Teratogenicity of bromocryptine in pregnant rats.

Authors:  D Weinstein; D Ben-Amitay; J G Schenker; A Ornoy; A A Hochberg; R Folman
Journal:  Arch Gynecol       Date:  1982

4.  Cushing's disease: clinical and laboratory response to bromocriptine therapy.

Authors:  M O de Pinho; R C Antunes; M B Lima; C C Francalanci; S Franco
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

5.  Five cases of cyclical Cushing's syndrome.

Authors:  A B Atkinson; A L Kennedy; D J Carson; D R Hadden; J A Weaver; B Sheridan
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-23

6.  Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.

Authors:  Michael Ezrokhi; Shuqin Luo; Yelena Trubitsyna; Anthony H Cincotta
Journal:  Diabetol Metab Syndr       Date:  2014-09-25       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.